| 000 | 01796 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250513171427.0 | ||
| 264 | 0 | _c19990413 | |
| 008 | 199904s 0 0 eng d | ||
| 022 | _a0024-3205 | ||
| 024 | 7 |
_a10.1016/s0024-3205(99)00004-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMesdjian, E | |
| 245 | 0 | 0 |
_aMetabolism of carbamazepine by CYP3A6: a model for in vitro drug interactions studies. _h[electronic resource] |
| 260 |
_bLife sciences _c1999 |
||
| 300 |
_a827-35 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xmetabolism |
| 650 | 0 | 4 |
_aAntibodies _xpharmacology |
| 650 | 0 | 4 |
_aAnticonvulsants _xmetabolism |
| 650 | 0 | 4 | _aAryl Hydrocarbon Hydroxylases |
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 |
_aCarbamazepine _xmetabolism |
| 650 | 0 | 4 | _aCytochrome P-450 Enzyme Inhibitors |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _ximmunology |
| 650 | 0 | 4 |
_aDextromethorphan _xmetabolism |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEnzyme Induction _xdrug effects |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xmetabolism |
| 650 | 0 | 4 |
_aEpilepsy _xdrug therapy |
| 650 | 0 | 4 |
_aHypnotics and Sedatives _xmetabolism |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMicrosomes, Liver _xdrug effects |
| 650 | 0 | 4 |
_aNifedipine _xmetabolism |
| 650 | 0 | 4 |
_aProtein Isoforms _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRabbits |
| 700 | 1 | _aSérée, E | |
| 700 | 1 | _aCharvet, B | |
| 700 | 1 | _aMirrione, A | |
| 700 | 1 | _aBourgarel-Rey, V | |
| 700 | 1 | _aDesobry, A | |
| 700 | 1 | _aBarra, Y | |
| 773 | 0 |
_tLife sciences _gvol. 64 _gno. 10 _gp. 827-35 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0024-3205(99)00004-1 _zAvailable from publisher's website |
| 999 |
_c10056085 _d10056085 |
||